Adagene has created a platform composed of unique, multi-purpose, antibody technologies and a growing pipeline of leading assets with novel MOAs. Empowered by precision engineering, Adagene identifies and selects antibody candidates that are most likely to achieve the desired biological effects. Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino acid sequence can adopt multiple structures and functions.
Suzhou City, China
Founded in 2011
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Public Company
Locations
1 Headquarter
Number of products
10 Products
Specialised areas
Therapeutics, Biotechnology, Medical
Adagene offers a wide range of products and services
Product
Dynamic Precision Library - Adagene
Go to product >
Product
新表位抗体(NEObody™) - Adagene
Go to product >
Product
动态精准抗体平台 - Adagene
Go to product >
Product
强力抗体(POWERbody™) - Adagene
Go to product >
Product
安全抗体(SAFEbody®) - Adagene
Go to product >
Product
SAFEbody - Adagene
Go to product >
Product
NEObody - Adagene
Go to product >
Product
POWERbody - Adagene
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
China
Overall risk estimation:
High
The ESG Data of countries are based on public sources
Environment
E
Grade (A-E)
View details
Social
C
Grade (A-E)
View details
Governance
E
Grade (A-E)
View details
Adagene operates in 1 country around the world
Get an overview of the locations of Adagene
Location
Country
State
City
Headquarter
China
Jiangsu
Suzhou City
Some frequent questions that have been asked about Adagene
Where is Adagene located?
The company headquarter of Adagene is located in Suzhou City, Jiangsu, China. It's worth noting, that the company may have more locations
How many employees does Adagene approximately have?
As of the latest available information Adagene has around 11-50 employees worldwide.
When was Adagene founded?
Adagene was founded in 2011
In which industries does Adagene mainly work?
The company Adagene has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Adagene
AvantGen
San Diego, United States
11-50 Employees
2006
We are laser-focused on getting what our partners need for the next stage. AvantGen provides a great platform and a dedicated, flexible, and communicative team that has resulted in success for multiple projects. Working with AvantGen on multiple antibody discovery projects was an outstanding experience. Interestingly, our popular AvantGeneer affinity maturation platform has been frequently used to optimize client antibodies that were originally discovered with hybridoma and human transgenic mouse platforms. Their innovative approach and collaborative mindset greatly contributed to the success of our program. Boosting the human innate immune system is a promising approach to cancer immunotherapy, and we have developed a Natural Killer (NK) cell engager platform. It’s important that both labeled and unlabeled antigens are QC’ed by provider, third party, and/or AvantGen.
Abtech Therapeutics
Marseille, France
1-10 Employees
-
We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.
Adivo
Planegg, Germany
1-10 Employees
2012
The adivo technology platform allows de-novo identification of a panel of antibodies to select a drug candidate with optimal functionality, developability and low risk of immunogenicity. At adivo, Kathrin is driving the financing and business development strategy of the company and is managing adivo’s existing alliances. At adivo, Markus is leading the transition of antibody lead candidates from the company´s discovery platform into clinical development in close collaboration with a variety of internal and external parties. At adivo, Philipp drives the target identification process and technology development, as well as antibody discovery for both proprietary and partnered programs. We are excited to announce the expansion of an existing global research collaboration and introduce our latest technology platform FELIX. By developing adivo’s fully canine-based antibody library towards commercialization, we hope that we will be able to generate therapeutics for dogs that are both well tolerated and efficacious,” Dr. In 2018, adivo was founded focussing on therapeutic antibodies for dogs for unmet medical needs such as cancer and chronic inflammatory conditions. The adivo team aims to initially address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future.
Adimab
Lebanon, United States
101-250 Employees
2007
We provide a full implementation of the Adimab Platform to enable your scientists to discover and optimize lead candidates within your existing workflow. We offer a suite of in vitro and in vivo discovery methods together with our engineered yeast to deliver therapeutic leads to our partners. We offer a variety of bispecific formats that cover a wide range of biological functionality.
Ab Studio
Hayward, United States
11-50 Employees
2017
We are a biotech startup in the San Francisco Bay Area founded in February 2017. Our goal is to close the gap between antibody discovery and therapeutic antibody development by developing the next generation of therapeutic antibodies. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, infectious diseases, and CNS diseases, by combining conventional approaches with computer-aided antibody design (CAAD). Our founder and lead scientists have extensive expertise in the fields of therapeutic antibody discovery, lead selection, engineering, humanization, and optimization. We believe in quality-by-design and have established several CAAD-based unique technology platforms for antibody development and are in the process of developing more platforms and therapeutics. Founder, Yue Liu, is a leading scientist with extensive expertise in therapeutic antibody discovery and computer-aided design. Joining Yue, the team is composed of experts in antibody engineering, B-cell cloning, cancer biology, immunology and virology.
GigaGen
South San Francisco, United States
11-50 Employees
2010
GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases. GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies. GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development. GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates. Biocentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute. GigaGen’s platform technologies significantly increase the productivity and speed of target and drug discovery, quickly filling a growing pipeline of transformative antibody drugs.